Datasets:

electricsheepafrica
/

counterfeit-arv-hiv-medicines

id int64	supply_chain string	facility_id string	facility_type string	region_type string	product_name string	drug_class string	treatment_line string	dosage_form string	reference_price_usd float64	WHO_prequalified int64	registered_product int64	from_pooled_procurement int64	manufacturer_origin string	year int64	quarter int64	quality_test_result string	sf_classification string	failure_mode string	API_content_pct float64	viral_suppression_impact int64	treatment_interruption int64	patient_population string	on_ART_duration_months int64
1	national_programme	ARV_0018	community_health_post	rural	TLD_tenofovir_lamivudine_dolutegravir	INSTI_based	first_line	tablet	0.12	0	1	0	Europe	2,024	4	pass	compliant	not_applicable	97.3	0	0	adult_female	39
2	national_programme	ARV_0156	private_pharmacy	peri_urban	TEE_tenofovir_lamivudine_efavirenz	NNRTI_based	first_line_legacy	tablet	0.08	1	1	1	China	2,023	3	pass	compliant	not_applicable	97.6	0	0	adolescent	44
3	national_programme	ARV_0135	ART_clinic	peri_urban	atazanavir_ritonavir	PI_based	second_line	tablet	0.25	1	1	0	local_SSA	2,024	4	pass	compliant	not_applicable	97.4	0	0	adult_female	23
4	national_programme	ARV_0093	community_health_post	urban	lopinavir_ritonavir	PI_based	second_line	tablet	0.2	0	1	0	local_SSA	2,022	1	pass	compliant	not_applicable	99.5	0	0	adult_female	10
5	national_programme	ARV_0048	ART_clinic	urban	abacavir_lamivudine_paediatric	NRTI	paediatric	dispersible	0.15	1	1	0	local_SSA	2,024	3	pass	compliant	not_applicable	97.7	0	0	adult_male	4
6	national_programme	ARV_0088	community_health_post	peri_urban	nevirapine_suspension	NNRTI	paediatric	suspension	0.08	0	1	0	South_Africa	2,022	3	fail	substandard	insufficient_API	49.5	0	1	adult_male	91
7	national_programme	ARV_0087	private_clinic	rural	dolutegravir_10mg_dispersible	INSTI	paediatric	dispersible	0.18	0	1	0	India	2,020	3	pass	compliant	not_applicable	96.6	0	0	adult_female	13
8	national_programme	ARV_0180	ART_clinic	peri_urban	darunavir_ritonavir	PI_based	third_line	tablet	0.8	1	1	1	South_Africa	2,022	3	pass	compliant	not_applicable	96.4	0	0	adolescent	36
9	national_programme	ARV_0099	district_hospital	rural	zidovudine_lamivudine	NRTI	legacy	tablet	0.06	0	1	1	India	2,020	3	pass	compliant	not_applicable	100.7	0	0	adult_male	11
10	national_programme	ARV_0161	ART_clinic	rural	cotrimoxazole_prophylaxis	OI_prophylaxis	prophylaxis	tablet	0.01	0	1	1	South_Africa	2,023	3	pass	compliant	not_applicable	97	0	0	adult_female	2
11	national_programme	ARV_0036	district_hospital	urban	fluconazole_200mg	OI_treatment	OI_treatment	capsule	0.05	1	1	1	unknown	2,023	2	pass	compliant	not_applicable	100.3	0	0	adult_male	195
12	national_programme	ARV_0084	private_pharmacy	urban	isoniazid_300mg_TPT	TB_preventive	TPT	tablet	0.02	1	1	0	South_Africa	2,023	2	pass	compliant	not_applicable	97.4	0	0	adult_female	22
13	national_programme	ARV_0057	private_pharmacy	rural	TLD_tenofovir_lamivudine_dolutegravir	INSTI_based	first_line	tablet	0.12	1	1	1	local_SSA	2,022	1	pass	compliant	not_applicable	102.5	0	0	paediatric	6
14	national_programme	ARV_0123	district_hospital	urban	TEE_tenofovir_lamivudine_efavirenz	NNRTI_based	first_line_legacy	tablet	0.08	0	1	0	China	2,022	4	pass	compliant	not_applicable	99.8	0	0	adult_female	20
15	national_programme	ARV_0198	ART_clinic	urban	atazanavir_ritonavir	PI_based	second_line	tablet	0.25	1	0	0	local_SSA	2,024	4	pass	compliant	not_applicable	99.6	0	0	adult_female	81
16	national_programme	ARV_0067	district_hospital	urban	lopinavir_ritonavir	PI_based	second_line	tablet	0.2	0	1	0	India	2,021	3	pass	compliant	not_applicable	98.6	0	0	adult_male	9
17	national_programme	ARV_0144	ART_clinic	urban	abacavir_lamivudine_paediatric	NRTI	paediatric	dispersible	0.15	0	0	0	India	2,020	4	pass	compliant	not_applicable	99.2	0	0	pregnant_woman	3
18	national_programme	ARV_0060	private_clinic	peri_urban	nevirapine_suspension	NNRTI	paediatric	suspension	0.08	1	1	0	local_SSA	2,021	3	pass	compliant	not_applicable	100	0	0	adult_female	23
19	national_programme	ARV_0027	private_clinic	rural	dolutegravir_10mg_dispersible	INSTI	paediatric	dispersible	0.18	1	0	1	South_Africa	2,023	2	pass	compliant	not_applicable	99.2	0	0	adult_female	72
20	national_programme	ARV_0034	informal_source	rural	darunavir_ritonavir	PI_based	third_line	tablet	0.8	1	1	1	India	2,024	3	pass	compliant	not_applicable	94.7	0	0	adult_female	89
21	national_programme	ARV_0186	private_clinic	peri_urban	zidovudine_lamivudine	NRTI	legacy	tablet	0.06	1	1	0	unknown	2,023	4	pass	compliant	not_applicable	96.4	0	0	pregnant_woman	61
22	national_programme	ARV_0191	ART_clinic	peri_urban	cotrimoxazole_prophylaxis	OI_prophylaxis	prophylaxis	tablet	0.01	1	0	1	India	2,024	1	pass	compliant	not_applicable	98.2	0	0	adult_male	18
23	national_programme	ARV_0108	ART_clinic	urban	fluconazole_200mg	OI_treatment	OI_treatment	capsule	0.05	1	1	0	India	2,022	1	pass	compliant	not_applicable	99	0	0	paediatric	2
24	national_programme	ARV_0099	district_hospital	urban	isoniazid_300mg_TPT	TB_preventive	TPT	tablet	0.02	0	1	1	India	2,023	1	pass	compliant	not_applicable	101.4	0	0	adult_male	96
25	national_programme	ARV_0138	private_pharmacy	rural	TLD_tenofovir_lamivudine_dolutegravir	INSTI_based	first_line	tablet	0.12	0	1	0	South_Africa	2,024	1	pass	compliant	not_applicable	98.5	0	0	adult_female	35
26	national_programme	ARV_0166	district_hospital	peri_urban	TEE_tenofovir_lamivudine_efavirenz	NNRTI_based	first_line_legacy	tablet	0.08	1	1	1	India	2,021	2	pass	compliant	not_applicable	100.7	0	0	adult_female	20
27	national_programme	ARV_0037	district_hospital	rural	atazanavir_ritonavir	PI_based	second_line	tablet	0.25	0	1	1	India	2,024	3	pass	compliant	not_applicable	100.7	0	0	adult_female	5
28	national_programme	ARV_0015	private_pharmacy	urban	lopinavir_ritonavir	PI_based	second_line	tablet	0.2	0	0	1	South_Africa	2,020	2	pass	compliant	not_applicable	100.5	0	0	adolescent	6
29	national_programme	ARV_0192	private_pharmacy	peri_urban	abacavir_lamivudine_paediatric	NRTI	paediatric	dispersible	0.15	0	1	0	India	2,023	4	pass	compliant	not_applicable	99.6	0	0	adult_female	21
30	national_programme	ARV_0095	community_health_post	rural	nevirapine_suspension	NNRTI	paediatric	suspension	0.08	0	1	0	unknown	2,021	2	fail	falsified	counterfeit_packaging	93.5	0	0	adult_female	34
31	national_programme	ARV_0163	district_hospital	urban	dolutegravir_10mg_dispersible	INSTI	paediatric	dispersible	0.18	1	1	1	unknown	2,022	4	pass	compliant	not_applicable	102	0	0	adult_female	156
32	national_programme	ARV_0072	community_health_post	urban	darunavir_ritonavir	PI_based	third_line	tablet	0.8	0	1	0	India	2,024	4	pass	compliant	not_applicable	95	0	0	adult_female	94
33	national_programme	ARV_0109	community_health_post	rural	zidovudine_lamivudine	NRTI	legacy	tablet	0.06	1	1	1	India	2,024	1	pass	compliant	not_applicable	96.2	0	0	adolescent	35
34	national_programme	ARV_0137	private_pharmacy	urban	cotrimoxazole_prophylaxis	OI_prophylaxis	prophylaxis	tablet	0.01	0	1	0	India	2,024	2	fail	substandard	insufficient_API	71.6	1	0	adult_male	1
35	national_programme	ARV_0032	private_clinic	rural	fluconazole_200mg	OI_treatment	OI_treatment	capsule	0.05	1	0	1	China	2,024	1	pass	compliant	not_applicable	101.2	0	0	paediatric	3
36	national_programme	ARV_0091	ART_clinic	peri_urban	isoniazid_300mg_TPT	TB_preventive	TPT	tablet	0.02	0	1	0	India	2,024	1	pass	compliant	not_applicable	98.3	0	0	pregnant_woman	42
37	national_programme	ARV_0150	ART_clinic	peri_urban	TLD_tenofovir_lamivudine_dolutegravir	INSTI_based	first_line	tablet	0.12	1	0	0	India	2,020	3	pass	compliant	not_applicable	96.9	0	0	adult_female	31
38	national_programme	ARV_0051	private_clinic	urban	TEE_tenofovir_lamivudine_efavirenz	NNRTI_based	first_line_legacy	tablet	0.08	0	1	0	local_SSA	2,023	3	pass	compliant	not_applicable	99.8	0	0	adult_female	16
39	national_programme	ARV_0182	ART_clinic	urban	atazanavir_ritonavir	PI_based	second_line	tablet	0.25	1	1	1	South_Africa	2,023	2	pass	compliant	not_applicable	97.3	0	0	adult_male	34
40	national_programme	ARV_0120	ART_clinic	peri_urban	lopinavir_ritonavir	PI_based	second_line	tablet	0.2	1	1	0	South_Africa	2,024	2	pass	compliant	not_applicable	99.4	0	0	adult_female	112
41	national_programme	ARV_0069	community_health_post	peri_urban	abacavir_lamivudine_paediatric	NRTI	paediatric	dispersible	0.15	1	1	0	unknown	2,024	3	pass	compliant	not_applicable	98.7	0	0	paediatric	19
42	national_programme	ARV_0104	community_health_post	urban	nevirapine_suspension	NNRTI	paediatric	suspension	0.08	1	0	1	India	2,022	4	pass	compliant	not_applicable	100.9	0	0	pregnant_woman	1
43	national_programme	ARV_0087	private_pharmacy	urban	dolutegravir_10mg_dispersible	INSTI	paediatric	dispersible	0.18	1	1	1	India	2,024	4	pass	compliant	not_applicable	99.9	0	0	adult_female	69
44	national_programme	ARV_0029	district_hospital	peri_urban	darunavir_ritonavir	PI_based	third_line	tablet	0.8	1	1	0	India	2,021	3	pass	compliant	not_applicable	102.3	0	0	adult_female	21
45	national_programme	ARV_0160	ART_clinic	peri_urban	zidovudine_lamivudine	NRTI	legacy	tablet	0.06	1	1	0	India	2,023	4	pass	compliant	not_applicable	97.1	0	0	adolescent	1
46	national_programme	ARV_0126	district_hospital	peri_urban	cotrimoxazole_prophylaxis	OI_prophylaxis	prophylaxis	tablet	0.01	0	1	1	India	2,024	1	pass	compliant	not_applicable	98.6	0	0	pregnant_woman	21
47	national_programme	ARV_0123	district_hospital	peri_urban	fluconazole_200mg	OI_treatment	OI_treatment	capsule	0.05	1	0	1	Europe	2,024	1	pass	compliant	not_applicable	98.4	0	0	adult_female	70
48	national_programme	ARV_0077	community_health_post	peri_urban	isoniazid_300mg_TPT	TB_preventive	TPT	tablet	0.02	1	1	0	South_Africa	2,021	2	pass	compliant	not_applicable	100.5	0	0	adult_male	149
49	national_programme	ARV_0138	district_hospital	peri_urban	TLD_tenofovir_lamivudine_dolutegravir	INSTI_based	first_line	tablet	0.12	1	1	0	South_Africa	2,024	2	pass	compliant	not_applicable	101.5	0	0	paediatric	36
50	national_programme	ARV_0103	informal_source	rural	TEE_tenofovir_lamivudine_efavirenz	NNRTI_based	first_line_legacy	tablet	0.08	0	1	0	India	2,023	3	pass	compliant	not_applicable	102.2	0	0	adolescent	28
51	national_programme	ARV_0164	private_pharmacy	urban	atazanavir_ritonavir	PI_based	second_line	tablet	0.25	1	1	0	India	2,024	3	pass	compliant	not_applicable	95.5	0	0	adult_female	22
52	national_programme	ARV_0130	private_clinic	rural	lopinavir_ritonavir	PI_based	second_line	tablet	0.2	0	0	1	India	2,020	1	pass	compliant	not_applicable	99.5	0	0	pregnant_woman	56
53	national_programme	ARV_0002	private_pharmacy	rural	abacavir_lamivudine_paediatric	NRTI	paediatric	dispersible	0.15	1	1	0	unknown	2,020	4	pass	compliant	not_applicable	97.8	0	0	adult_male	93
54	national_programme	ARV_0140	private_clinic	urban	nevirapine_suspension	NNRTI	paediatric	suspension	0.08	0	1	0	India	2,023	4	pass	compliant	not_applicable	98.4	0	0	paediatric	38
55	national_programme	ARV_0136	district_hospital	rural	dolutegravir_10mg_dispersible	INSTI	paediatric	dispersible	0.18	0	0	1	India	2,021	1	pass	compliant	not_applicable	95.5	0	0	adult_female	23
56	national_programme	ARV_0044	ART_clinic	urban	darunavir_ritonavir	PI_based	third_line	tablet	0.8	1	1	1	India	2,023	2	pass	compliant	not_applicable	98.4	0	0	adolescent	18
57	national_programme	ARV_0101	district_hospital	rural	zidovudine_lamivudine	NRTI	legacy	tablet	0.06	1	1	0	India	2,024	3	pass	compliant	not_applicable	99.5	0	0	adult_male	6
58	national_programme	ARV_0060	ART_clinic	rural	cotrimoxazole_prophylaxis	OI_prophylaxis	prophylaxis	tablet	0.01	1	1	0	Europe	2,022	2	pass	compliant	not_applicable	101.5	0	0	pregnant_woman	27
59	national_programme	ARV_0134	private_pharmacy	urban	fluconazole_200mg	OI_treatment	OI_treatment	capsule	0.05	0	1	0	unknown	2,023	4	pass	compliant	not_applicable	100.9	0	0	adolescent	2
60	national_programme	ARV_0059	district_hospital	urban	isoniazid_300mg_TPT	TB_preventive	TPT	tablet	0.02	1	1	1	India	2,021	1	pass	compliant	not_applicable	101.1	0	0	pregnant_woman	17
61	national_programme	ARV_0195	district_hospital	peri_urban	TLD_tenofovir_lamivudine_dolutegravir	INSTI_based	first_line	tablet	0.12	1	1	0	India	2,023	2	pass	compliant	not_applicable	95.9	0	0	adult_female	65
62	national_programme	ARV_0093	district_hospital	urban	TEE_tenofovir_lamivudine_efavirenz	NNRTI_based	first_line_legacy	tablet	0.08	1	1	0	India	2,022	4	pass	compliant	not_applicable	96.7	0	0	adult_female	24
63	national_programme	ARV_0039	ART_clinic	urban	atazanavir_ritonavir	PI_based	second_line	tablet	0.25	0	1	1	India	2,021	1	pass	compliant	not_applicable	101	0	0	adult_female	90
64	national_programme	ARV_0137	ART_clinic	rural	lopinavir_ritonavir	PI_based	second_line	tablet	0.2	0	1	0	unknown	2,022	4	pass	compliant	not_applicable	97	0	0	adult_female	17
65	national_programme	ARV_0147	district_hospital	rural	abacavir_lamivudine_paediatric	NRTI	paediatric	dispersible	0.15	0	1	1	India	2,020	4	pass	compliant	not_applicable	95.4	0	0	adult_male	9
66	national_programme	ARV_0132	private_pharmacy	rural	nevirapine_suspension	NNRTI	paediatric	suspension	0.08	1	0	0	India	2,021	3	pass	compliant	not_applicable	99.8	0	0	adult_female	51
67	national_programme	ARV_0053	ART_clinic	rural	dolutegravir_10mg_dispersible	INSTI	paediatric	dispersible	0.18	0	1	0	unknown	2,023	1	pass	compliant	not_applicable	98.7	0	0	adult_male	51
68	national_programme	ARV_0027	private_clinic	rural	darunavir_ritonavir	PI_based	third_line	tablet	0.8	1	1	1	unknown	2,022	2	pass	compliant	not_applicable	96.8	0	0	adult_female	42
69	national_programme	ARV_0106	private_clinic	rural	zidovudine_lamivudine	NRTI	legacy	tablet	0.06	0	1	0	India	2,024	3	pass	compliant	not_applicable	98	0	0	adult_male	40
70	national_programme	ARV_0131	private_clinic	urban	cotrimoxazole_prophylaxis	OI_prophylaxis	prophylaxis	tablet	0.01	0	1	1	unknown	2,024	2	pass	compliant	not_applicable	94.8	0	0	pregnant_woman	55
71	national_programme	ARV_0129	community_health_post	rural	fluconazole_200mg	OI_treatment	OI_treatment	capsule	0.05	0	1	0	India	2,024	2	pass	compliant	not_applicable	97.2	0	0	adult_male	24
72	national_programme	ARV_0086	ART_clinic	rural	isoniazid_300mg_TPT	TB_preventive	TPT	tablet	0.02	1	1	0	India	2,022	3	pass	compliant	not_applicable	100.7	0	0	adult_female	22
73	national_programme	ARV_0115	community_health_post	urban	TLD_tenofovir_lamivudine_dolutegravir	INSTI_based	first_line	tablet	0.12	1	1	1	India	2,023	4	pass	compliant	not_applicable	100.3	0	0	adult_male	8
74	national_programme	ARV_0095	private_pharmacy	urban	TEE_tenofovir_lamivudine_efavirenz	NNRTI_based	first_line_legacy	tablet	0.08	1	1	0	India	2,022	4	pass	compliant	not_applicable	97	0	0	adolescent	204
75	national_programme	ARV_0135	ART_clinic	urban	atazanavir_ritonavir	PI_based	second_line	tablet	0.25	1	1	0	unknown	2,024	2	pass	compliant	not_applicable	96.7	0	0	adult_male	6
76	national_programme	ARV_0188	private_clinic	urban	lopinavir_ritonavir	PI_based	second_line	tablet	0.2	0	1	0	India	2,022	2	pass	compliant	not_applicable	101.1	0	0	adult_female	102
77	national_programme	ARV_0148	district_hospital	peri_urban	abacavir_lamivudine_paediatric	NRTI	paediatric	dispersible	0.15	0	1	1	unknown	2,021	2	pass	compliant	not_applicable	96.4	0	0	adult_male	70
78	national_programme	ARV_0123	community_health_post	peri_urban	nevirapine_suspension	NNRTI	paediatric	suspension	0.08	1	1	0	unknown	2,022	1	pass	compliant	not_applicable	101.7	0	0	adult_male	12
79	national_programme	ARV_0008	private_pharmacy	rural	dolutegravir_10mg_dispersible	INSTI	paediatric	dispersible	0.18	1	1	0	India	2,022	4	pass	compliant	not_applicable	99	0	0	adolescent	51
80	national_programme	ARV_0167	ART_clinic	peri_urban	darunavir_ritonavir	PI_based	third_line	tablet	0.8	1	1	1	India	2,024	4	pass	compliant	not_applicable	100	0	0	adult_female	15
81	national_programme	ARV_0106	ART_clinic	rural	zidovudine_lamivudine	NRTI	legacy	tablet	0.06	0	1	1	India	2,024	3	pass	compliant	not_applicable	97.6	0	0	adult_female	120
82	national_programme	ARV_0131	private_pharmacy	rural	cotrimoxazole_prophylaxis	OI_prophylaxis	prophylaxis	tablet	0.01	1	0	1	South_Africa	2,020	3	pass	compliant	not_applicable	98.5	0	0	adult_male	17
83	national_programme	ARV_0159	ART_clinic	peri_urban	fluconazole_200mg	OI_treatment	OI_treatment	capsule	0.05	1	0	1	local_SSA	2,023	1	pass	compliant	not_applicable	96.2	0	0	adult_female	94
84	national_programme	ARV_0105	ART_clinic	peri_urban	isoniazid_300mg_TPT	TB_preventive	TPT	tablet	0.02	0	1	1	unknown	2,024	2	pass	compliant	not_applicable	98.4	0	0	pregnant_woman	5
85	national_programme	ARV_0072	district_hospital	rural	TLD_tenofovir_lamivudine_dolutegravir	INSTI_based	first_line	tablet	0.12	1	1	0	India	2,024	4	pass	compliant	not_applicable	98.9	0	0	adult_female	11
86	national_programme	ARV_0093	ART_clinic	urban	TEE_tenofovir_lamivudine_efavirenz	NNRTI_based	first_line_legacy	tablet	0.08	0	1	0	India	2,022	2	pass	compliant	not_applicable	98	0	0	paediatric	12
87	national_programme	ARV_0182	ART_clinic	urban	atazanavir_ritonavir	PI_based	second_line	tablet	0.25	1	1	0	unknown	2,021	3	pass	compliant	not_applicable	94.8	0	0	adolescent	35
88	national_programme	ARV_0149	private_clinic	urban	lopinavir_ritonavir	PI_based	second_line	tablet	0.2	0	1	0	India	2,022	2	pass	compliant	not_applicable	101	0	0	adult_female	105
89	national_programme	ARV_0169	district_hospital	peri_urban	abacavir_lamivudine_paediatric	NRTI	paediatric	dispersible	0.15	1	1	1	India	2,024	4	pass	compliant	not_applicable	97.1	0	0	adolescent	61
90	national_programme	ARV_0199	private_pharmacy	peri_urban	nevirapine_suspension	NNRTI	paediatric	suspension	0.08	1	1	0	India	2,022	4	pass	compliant	not_applicable	98.7	0	0	adult_male	111
91	national_programme	ARV_0058	ART_clinic	urban	dolutegravir_10mg_dispersible	INSTI	paediatric	dispersible	0.18	1	1	0	India	2,024	4	pass	compliant	not_applicable	98.5	0	0	adolescent	16
92	national_programme	ARV_0189	community_health_post	peri_urban	darunavir_ritonavir	PI_based	third_line	tablet	0.8	0	0	1	India	2,024	1	pass	compliant	not_applicable	99.2	0	0	pregnant_woman	5
93	national_programme	ARV_0142	ART_clinic	peri_urban	zidovudine_lamivudine	NRTI	legacy	tablet	0.06	0	1	0	local_SSA	2,024	4	pass	compliant	not_applicable	98.9	0	0	adult_male	14
94	national_programme	ARV_0060	community_health_post	urban	cotrimoxazole_prophylaxis	OI_prophylaxis	prophylaxis	tablet	0.01	0	1	0	China	2,024	2	pass	compliant	not_applicable	100.7	0	0	pregnant_woman	106
95	national_programme	ARV_0034	private_pharmacy	urban	fluconazole_200mg	OI_treatment	OI_treatment	capsule	0.05	0	1	1	India	2,020	2	pass	compliant	not_applicable	99	0	0	adult_female	62
96	national_programme	ARV_0020	private_clinic	rural	isoniazid_300mg_TPT	TB_preventive	TPT	tablet	0.02	1	1	0	China	2,023	1	pass	compliant	not_applicable	101.8	0	0	adult_female	49
97	national_programme	ARV_0117	private_pharmacy	peri_urban	TLD_tenofovir_lamivudine_dolutegravir	INSTI_based	first_line	tablet	0.12	0	1	1	India	2,021	2	pass	compliant	not_applicable	100.4	0	0	adult_male	8
98	national_programme	ARV_0033	private_pharmacy	urban	TEE_tenofovir_lamivudine_efavirenz	NNRTI_based	first_line_legacy	tablet	0.08	0	1	0	India	2,022	1	pass	compliant	not_applicable	101.9	0	0	paediatric	11
99	national_programme	ARV_0123	private_clinic	urban	atazanavir_ritonavir	PI_based	second_line	tablet	0.25	0	1	0	China	2,024	1	fail	falsified	counterfeit_packaging	65.9	0	0	paediatric	15
100	national_programme	ARV_0032	district_hospital	peri_urban	lopinavir_ritonavir	PI_based	second_line	tablet	0.2	1	1	0	India	2,020	2	pass	compliant	not_applicable	98.4	0	0	adult_female	19

End of preview. Expand in Data Studio

Counterfeit ARV & HIV Medicines Dataset

Abstract

This dataset provides 30,000 simulated ARV quality observations (10,000 per scenario) across three supply chain tiers in sub-Saharan Africa. Each record represents one ARV/HIV medicine sample tested, capturing drug class, WHO prequalification status, pooled procurement origin, API content, failure mode, viral suppression impact, HIV drug resistance emergence, and treatment interruption. Three scenarios: PEPFAR/Global Fund supply (0.2% SF), national programme (3.6%), private/informal market (58.5%). Demonstrates the critical role of quality-assured supply chains in maintaining ART efficacy.

This dataset is entirely simulated. It must not be used for clinical or procurement decisions.

1. Introduction

ARVs are among the best-protected medicine categories in SSA due to PEPFAR and Global Fund pooled procurement through WHO-prequalified manufacturers. However, outside donor-funded supply chains, ARV quality deteriorates significantly. SF ARVs with subtherapeutic concentrations drive HIV drug resistance, threatening the 30.7 million people on ART globally (UNAIDS 2023). Pretreatment NNRTI resistance exceeds 10% in multiple SSA countries.

2. Parameterization Evidence (v2.0)

Parameter	Value Used	Source	Year
ARVs 2.3% of WHO GSM reports	2.3%	WHO GSM	2017
PEPFAR/GF SF rate <2%	<2%	PEPFAR quality assurance	2023
30.7M on ART globally	30.7M	UNAIDS	2023
Pretreatment NNRTI resistance >10%	>10%	WHO HIV drug resistance	2021
WHO PQ share in donor supply	>90%	Global Fund procurement	2023

3. Schema

Column	Type	Description
supply_chain	categorical	donor_funded / national_programme / private_informal
product_name	categorical	12 ARV/HIV products
drug_class	categorical	INSTI / NNRTI / PI / NRTI / OI
treatment_line	categorical	first_line / second_line / third_line / paediatric
WHO_prequalified	binary	WHO PQ status
from_pooled_procurement	binary	PEPFAR/GF procurement
quality_test_result	binary	pass / fail
sf_classification	categorical	compliant / substandard / falsified
API_content_pct	float	API as % of label
viral_suppression_impact	binary	Loss of viral suppression
resistance_emergence	binary	HIV drug resistance emergence
treatment_interruption	binary	ART interruption
patient_population	categorical	adult / pregnant / paediatric / adolescent

4. Validation

Validation Report

5. Usage

from datasets import load_dataset
dataset = load_dataset("electricsheepafrica/counterfeit-arv-hiv-medicines", "national_programme_mixed")
df = dataset["train"].to_pandas()
print(df.groupby('supply_chain')['resistance_emergence'].mean())

6. Limitations

Simulated: Not from real PEPFAR/GF quality assurance data.
Simplified resistance: Binary rather than genotypic resistance modelling.
No viral load data: Suppression impact not linked to actual VL measurements.

7. References

WHO (2017). ARVs 2.3% of SF reports to WHO GSM.
PEPFAR. Quality assurance in ARV procurement.
UNAIDS (2023). 30.7M people on ART globally.
WHO (2021). HIV drug resistance report. Pretreatment NNRTI resistance.
Global Fund. Pooled procurement mechanism.

Citation

@dataset{esa_sf_arv_2025,
  title   = {Counterfeit ARV and HIV Medicines Dataset},
  author  = {{Electric Sheep Africa}},
  year    = {2025},
  publisher = {Hugging Face},
  url     = {https://huggingface.co/datasets/electricsheepafrica/counterfeit-arv-hiv-medicines}
}

License

CC-BY-4.0

Downloads last month: 39